




归创通桥
ZYLOX-TONBRIDGE



2021 Annual Results Presentation

APRIL 2022

Disclaimer

This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase securities of Zylox-Tonbridge Medical Technology Co., Ltd. (the "Company").

This presentation does not constitute or contain an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities in any jurisdiction in which the making of such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise be in compliance with the laws and regulations of such jurisdiction, and neither this presentation nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Securities may not be offered or sold in the United States absent registration or an available exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). All the information in this presentation has been provided by the Company and has not been independently verified by its advisers or any of their respective affiliates or associates (collectively, "advisers"). No representation, warranty or undertaking, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company or any of its subsidiaries or by its advisers or representatives as to the fairness, accuracy, completeness or correctness of, this presentation or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed.

This presentation is not intended to provide the basis for evaluating, and should not be considered a recommendation with respect to, any transaction or other matter. Any analyses included herein are not and do not purport to be appraisals of the assets or business of the Company or any of its subsidiaries or affiliates. Nothing in this presentation should be construed as regulatory, valuation, legal, tax, accounting or investment advice. Before you enter into any transaction, you should ensure that you will be responsible for conducting your own due diligence investigation with respect to the Company and fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisors and legal and/or tax experts. Any decision to purchase securities of the Company in any public or private offering should be made solely on the basis of the prospectus and/or international offering circular to be prepared by the Company in relation to any such contemplated offering together with any supplementary pricing information. This presentation contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of section 2(1) Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong) (the "Companies Ordinance"), or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 38B of the Companies Ordinance or an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "Securities and Futures Ordinance") or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong, and is subject to material change without notice.

The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects", "believes" and "anticipates" and words of similar import. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisers or representatives are unaware. These forward looking statements are not a guarantee of future performance. Against the background of these uncertainties, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation is confidential and must not be copied, reproduced, distributed or passed (in whole or in part) to any other person at any time without the prior written consent of the Company or its advisers.

By accepting this presentation, the recipient has agreed, upon request, to return promptly all material received from the Company or its advisers (including this presentation) without retaining any copies. In furnishing this presentation, the Company and its advisers or representatives undertake no obligation to provide the recipient with access to any additional information or to update this presentation or to correct any inaccuracies therein which may become apparent.

By reading and attending this presentation, you agree to be bound by the foregoing restrictions, and you shall be deemed to have represented to us that you (and any customers you represent) are either (a) a qualified institutional buyer (as defined in Rule 144A under the U.S. Securities Act) or (b) outside the United States (within the meaning of Regulation S under the U.S. Securities Act). You also represent that you (and any customers you represent) are "professional investors" described in Part I of Schedule 1 to the Securities and Futures Ordinance and any subsidiary legislation thereunder (including but not limited to the Securities and Futures (Professional Investor) Rules (Chapter 571D of the Laws of Hong Kong)).

The distribution of this presentation in any jurisdiction may be restricted by law and persons in possession of this presentation should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.

Any prospective purchaser interested in buying securities of or evaluating the Company is recommended to seek its own independent legal, tax, financial and other professional advice.

Agenda

1

Business Highlights



2

Product and Business Updates



3


Financial Updates



4

Summary





SECTION 1



归创通桥
ZYLOX-TONBRIDGE

Business Highlights

Efficient Product R&D Lays a Solid Foundation for Continuous Growth

Achieve the Goal of Approved Products in 2021

Products in China ⁽¹⁾	Approval Time in 2021			
	Q1	Q2	Q3	Q4
1 Intracranial Balloon Catheter (Rx)				
2 Distal Access Catheter				
3 Endovascular Snare				
4 Balloon Guiding Catheter				
5 Microcatheter for Clot Retriever	Ahead			
6 Neurovascular Embolization Coils	Ahead			
7 Intracranial Support Catheter				
8 Microcatheter for Coiling				


R&D Pipelines Progressed Successfully



Flow Diverter



Peripheral Venous Stent System




Intracranial Drug Coated Balloon Catheter



Suture-mediated Closure System



IVL System



Pan-Vascular Robotics⁽²⁾


Notes:

- Two products were approved in the CE market simultaneously, namely Aspiration Catheter and Microcatheter for Clot Retriever
- Our strategic partner is responsible for the R&D work and we provide development support

Commercialization of High-quality Products Triggered Rapid Revenue Growth


Rapid Revenue Growth in 2021

(RMB in thousands)



Sufficient Funds and Efficient Operations

(RMB in thousands)



Notes:

1. Including cash and cash equivalents and term deposits
2. Including the PPE and land use right investment



SECTION 2



Product and Business Updates

Robust R&D Pipelines Bolster the Long-term Growth



41 new products expected to be approved domestically in the upcoming 4 years

16




Neurovascular
Interventional Products

23

Peripheral-vascular
Interventional Products

2

Vascular Closure
Devices

Category	As of Dec 31, 2021	2022	2023	2024	2025
	14 approved products	9 products ⁽¹⁾	13 products	12 products	7 products
 Neurovascular	<p>9 Approved</p> <p>Including Thrombite Clot Retriever Device, Intracranial Support Catheter, Balloon Guiding Catheter and Neurovascular Embolization Coils</p>	<p>3</p> <p>Including Aspiration Catheter, Neurovascular Guidewire and Carotid RX PTA Balloon Catheter</p>	<p>7</p> <p>Including Second Generation Thrombite® CRD, Second Generation Neurovascular Embolization Coils and Embolic Protection System</p>	<p>3</p> <p>Including Flow Diverter and Intracranial Drug Coated Balloon Catheter</p>	<p>3</p> <p>Including Stent for Stent Assisted Coiling and Carotid Stent</p>
 Peripheral-vascular	<p>5 Approved</p> <p>Including Drug Coated Balloon Catheter, PTA Balloon Catheter, High Pressure PTA Balloon Catheter, and Endovascular Snare</p>	<p>6</p> <p>Including Second Generation Drug Coated Balloon Catheter, Retrievable Inferior Vena Cava Filter and Endovascular RFA Catheter</p>	<p>5</p> <p>Including Peripheral Venous Stent System, Peripheral Stent System, and TIPS Access Set</p>	<p>8</p> <p>Including Drug Coated PTA Balloon Catheter-AV Fistula, Drug Coated PTA Balloon Catheter-BTK, and Multi-spot Stent System</p>	<p>4</p> <p>Including Peripheral Drug-Eluting Stent System and Thoracic Aorta Stent Graft System</p>
 Vascular Closure Devices			<p>1</p> <p>Suture-mediated Closure System</p>	<p>1</p> <p>Vascular Closure System</p>	

(1) Two products have been approved by NMPA since the beginning of 2022, namely Carotid RX PTA Balloon Catheter and PTA Balloon Catheter – Large Diameter

Products Update - Neurovascular Interventional Portfolio




Diseases	Intracranial Ischemic Stroke	Intracranial Hemorrhagic Stroke	Intracranial Stenosis	Carotid Artery Stenosis
Key Products	<ul style="list-style-type: none"> • Thrombite® CRD / Approved by NMPA in Sep 2020 • Balloon Guiding Catheter / Approved by NMPA in Jun 2021 • Second Generation Thrombite® CRD / 2023 • Aspiration Catheter / 2022 • Aspiration Pump System / 2023 	<ul style="list-style-type: none"> • Neurovascular Embolization Coils / Approved by NMPA in Sep 2021 • Second Generation Neurovascular Embolization Coils / 2023 • Microcatheter for Coiling / Approved by NMPA in Dec 2021 • Microcatheter for Flow Diverter / 2023 • Flow Diverter / 2024 • SAC / 2025 	<ul style="list-style-type: none"> • Intracranial Balloon Catheter (Rx) / Approved by NMPA in Mar 2021 • Intracranial balloon catheter(OTW) / 2023 • Microcatheter for Intracranial Stent / 2023 • Intracranial Drug Coated Balloon Catheter / 2024 • Intracranial Stent System / 2025 	<ul style="list-style-type: none"> • Carotid RX Balloon Catheter / Approved by NMPA in March 2022 • Embolic Protection System / 2023 • Carotid Stent / 2025
Intracranial Access Products	<ul style="list-style-type: none"> • Intracranial Support Catheter / Approved by NMPA in September 2020 • Microcatheter for Clot Retriever / Approved by NMPA in August 2021 • Distal Access Catheter / Approved by NMPA in March 2021 • Intracranial Support Catheter / Approved by NMPA in November 2021 • Neurovascular Guidewire / 2022 • Radial Access Catheter / 2024 			




Neurovascular - Rapid Revenue Growth

Revenue of Neurovascular Products



10 Products Approved in China and CE




Neurovascular - Products Expected to be Approved in 2022



Aspiration Catheter



Neurovascular Guidewire



Carotid RX PTA Balloon Catheter (1)



Effects:

- Expected to be used for revascularization in patients with acute ischemic stroke caused by intracranial large vessel occlusion

Advantages:

- More specifications. Able to reach farther and smaller blood vessels, stronger suction effect
- Excellent anti-flat tube design, uneasy to collapse

Effects:

- Expected to be used in neurovascular and peripheral vessels, and can be used for the guidance and positioning of catheters and other devices

Advantages:

- Better support
- Good traceability

Effects:


- Intended for percutaneous transluminal angioplasty in the peripheral vascular system

Advantages:

- Catheter design with reinforcing wire for superior push performance
- Fast exchange
- Short pressure relief time (average 8s), saving operation time

(1) approved by NMPA on March 31,2022

Neurovascular - Products Expected to be Approved in 2023



**Second Generation
Clot Retriever Device**



Effects:

- Expected to be used for the treatment of removing thrombus blocked in intracranial blood vessels within 8 hours of ischemic stroke to restore blood flow

Advantages:

- Whole body imaging, easier to confirm the position
- Pushing the guidewire and stepping on the wire: reminding the doctor the position of stent, which is safer



**Second Generation
Neurovascular
Embolization Coils**




Effects:

- Dense embolization of aneurysms with excellent basketing effect and extremely soft filling, closing loops

Advantages:

- Better push performance
- Stronger basket stability



Embolic Protection System



Effects:

- Intended for containment and removal of embolic material during carotid angioplasty and stenting

Advantages:

- More flexible guidewire design
- Excellent anti-displacement performance, excellent tracking and tactile feedback



Neurovascular - Key Hemorrhagic Stroke Products



Flow Diverter

Simultaneous advancement of clinical trials for 2 indications


- ✓ Small unruptured aneurysms (OPC) **completed enrollment in November 2021**
- ✓ Large unruptured aneurysm RCT, more than half of which has been enrolled, is **expected to complete enrollment in 2022**



Doctor Feedback

“ The Ton-Bridge Kylin (‘通桥麒麟’) Flow Diverter has a good performance with smooth pushing process, the adherence is judged well after release, the visualization is obvious, the aneurysm contrast agent is retained, and the parent artery is unobstructed. The operation is very successful and hope the patient will have a good prognosis and recover soon. ”

Evaluation according to the effect of the surgeries that have been completed



Competitive Advantages

- Every wire is wrapped with **imaging wires**, which enables the physician to **accurately position and deploy the stent** at the site of aneurysm
- The distal end is **close-loop** using loop-weaving technologies which can **reduce the irritation and damage** to the blood vessels upon release
- Both ends of are specially designed to be **slightly wider**, ensuring **full adherence to the vessel wall** to support the embolization process



Products Update - Peripheral-vascular Interventional Portfolio



Diseases	Arterial	Venous	Hemodialysis Access	
<p>Key Products</p>	<ul style="list-style-type: none"> • UltraFree® Drug Coated PTA Balloon Catheter/ Launched • Second Generation UltraFree® Drug Coated PTA Balloon Catheter / 2022 • PTA Balloon Catheter / Launched • Second Generation PTA Balloon Catheter/ 2022 • Peripheral Stent System / 2023 • Peripheral Drug-Eluting Stent System / 2025 • Endovascular Snare / Launched • PTA Scoring Balloon Catheter / 2024 • Multi-spot Stent System / 2024 • Drug Coated PTA Balloon Catheter-BTK / 2024 • IVL System / 2025 	<ul style="list-style-type: none"> • Snare Retrieval Kit for IVC Filter / Launched • Endovascular RFA Catheter / 2022 • Radiofrequency Generator / 2023 • PTA Balloon Catheter - Large Diameter / Approved by NMPA in April 2022 • Infusion Catheter / 2023 • Peripheral Venous Stent System / 2023 • Varicose Vein Closure System / 2024 • Peripheral Thrombectomy System / 2024 • Retrievable Inferior Vena Cava Filter/ 2022 • Mechanical Thrombectomy Device / 2025 	<ul style="list-style-type: none"> • High Pressure PTA Balloon Catheter / Launched • Second Generation High Pressure PTA Balloon Catheter / 2022 • Drug Coated PTA Balloon Catheter-AV Fistula / 2024 	
Diseases	Aortic Intervention	Peripheral Embolization Intervention	Radiological Intervention	Vascular Closure
<p>Key Products</p>	<ul style="list-style-type: none"> • Thoracic Aorta Stent Graft System / 2025 	<ul style="list-style-type: none"> • Peripheral Detachable Embolization Coils / 2024 	<ul style="list-style-type: none"> • TIPS Access Set / 2023 • TIPS Endoprosthesis / 2024 	<ul style="list-style-type: none"> • Suture-mediated Closure System / 2023 • Vascular Closure System / 2024




Peripheral-vascular - Rapid Revenue Growth



Revenue of Peripheral-vascular Products

5 Products Approved in China and CE Respectively



Drug Coated PTA Balloon Catheter



High Pressure PTA Balloon Catheter



PTA Balloon Catheter




Snare Retrieval Kit for IVC Filter



Peripheral-vascular – Products Expected To be Approved in 2022




Arterial



UltraFree® Drug Coated PTA Balloon Catheter II

For the treatment of peripheral arterial stenosis and occlusive disease and to slow the occurrence of restenosis



PTA Balloon Catheter II

For the treatment of peripheral arterial stenosis and occlusive disease

Venous



Endovenous Radiofrequency Ablation (RFA) Catheter

Efficient treatment of the great saphenous vein with varicose veins using radiofrequency thermal closure technology



Retrievable Inferior Vena Cava Filter


Can be temporarily or permanently placed in the vena cava to capture free deep vein thrombosis and prevent fatal pulmonary embolism



PTA Balloon Catheter - Large Diameter (1)

For dilation of large blood vessels, especially venous blood vessels

Hemodialysis Access



High Pressure PTA Balloon Catheter II

Provide high-pressure expansion capability, perform high-pressure expansion and treatment for highly stenotic hemodialysis access lesions, and restore blood flow

(1) approved by NMPA on April 6, 2022




Peripheral-vascular - Product Updates






Intravascular Lithotripsy (IVL) System


Product Structure





Product Features

-  **Circuit design with independent IP rights**
 - Submit nearly 10 invention patent applications
-  **Intelligent Energy Control System**
 - High lithotripsy effectiveness, providing stable and effective intravascular lithotripsy energy
 - High lithotripsy safety while avoiding damage to vessels and catheters
-  **Unique shock wave guide technology - potentially drug-carrying**

Registration Progress




Peripheral-vascular - Full Suite Solutions for Venous Diseases



Peripheral-vascular - Product Updates

Mechanical Thrombectomy Device

Product Structure



Product Features



Utilize a purely mechanical thrombectomy method for removal of emboli and thrombi from pulmonary vessels by large bore aspiration and mechanical thrombectomy without thrombolysis



Combines the advantages of catheter-based mechanical thrombectomy




Submission of type test in 2021, clinical start in 2022, approval in 2025

Disease Introduction

- Venous thromboembolism (VTE) refers to a group of disorders in which blood coagulates abnormally in the venous system due to various causes such as venous blood stagnation, venous intimal injury, or hypercoagulation, including pulmonary thromboembolism (PTE) and Deep vein thrombosis (DVT)
- About 90% of pulmonary embolisms come from the deep venous system of the lower extremities. Therefore, effective prevention of lower extremity DVT can effectively prevent PTE
- VTE occurs in about 1 to 2 per 1,000 people each year, and in the US, there are about 300,000 to 600,000 VTEs per year. About one-third of all patients with newly diagnosed VTE have PTE, with or without DVT, and it is estimated that up to one-quarter of PTE patients experience sudden death

Market Outlook

Prevalence of Pulmonary Embolism in China (Thousand)




Product Updates - Overseas Portfolio

Product	Phase			Expected Commercial Launch Year	
	Preclinical	Clinical Trials	Registration & Approval		
Peripheral-vascular Interventional Devices	UltraFree® Drug Coated PTA Balloon Catheter	CE	Exempted from clinical trial requirement	CE Launched	
	UltraFree® Drug Coated PTA Balloon Catheter II	MDR Clinical Preparation		2026	
	PTA Balloon Catheter	CE	Exempted from clinical trial requirement	CE Launched	
	Peripheral Stent System	CE	Exempted from clinical trial requirement	CE Launched	
	Peripheral Drug-Eluting Stent System	CE	Exempted from clinical trial requirement	CE Launched	
	High Pressure PTA Balloon Catheter	CE	Exempted from clinical trial requirement	CE Launched	
	Peripheral Venous Stent System	MDR Registration Preparation		2024	
	IVL System	MDR Clinical Preparation		2024	
	Neurovascular Interventional Devices	Thrombite® Clot Retriever Device	CE	Exempted from clinical trial requirement	CE Launched
		Aspiration Catheter	CE	Exempted from clinical trial requirement	CE Launched
Microcatheter for Clot Retriever		CE	Exempted from clinical trial requirement	CE Launched	
Neurovascular Embolization Coils		MDR Registration Preparation		2023	
Flow Diverter		FDA 510K Registration Preparation		2023	
	MDR Clinical Preparation		2024		




In 2021, overseas revenue was RMB3.46MM, accounting for ~2%



8 products approved and will continue to increase investment
 Successfully distributed in more than 10 countries
 With the enrichment of pipelines and the construction of channels, we expect rapid growth in the future

CE Considering that clinical evaluation has been provided, under the EU MDD directive, the product has obtained CE marking without clinical trials



SECTION 3




Financial Updates

Rapid Growth Driven by Successful R&D and Commercialization

Rapid Revenue Growth in 2021


(RMB in thousands)



- Peripheral-vascular Interventive Devices
- Neurovascular Interventive Devices

GPM Improves with Sales Optimization

(RMB in thousands)




- Gross Profit

Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years

Adjusted Net Loss


(RMB in thousands)



- Adjusted net loss
- Share-based compensation (SBC)
- Listing expenses⁽¹⁾

2021 Cash Status

(RMB in thousands)



- Total funds at the beginning of the year⁽²⁾
- Cash flow from financing activities
- Cash flow from operating activities
- Cash flow from investing activities⁽³⁾
- Other⁽⁴⁾
- Total funds at the end of the year⁽²⁾

Notes:

1. Excludes SBC and listing expenses. We consider SBC and listing fees as non-operating or one-time expenses that do not affect ongoing operating performance. We believe that by excluding the potential impact of SBC and listing expenses, the adjusted net loss provides investors with useful information to assist in comparing operating results across periods
2. Total funds at the beginning and end of the year include cash and cash equivalents, term deposits, wealth management products
3. Only including the PPE and land use right investment
4. Others referring to fair value changes, foreign exchange losses, etc.

Increasing Operating Expenses Level in Line with Development

Selling and Distribution Expenses

R&D Expenses

Administrative Expenses

(RMB in thousands)

(RMB in thousands)

(RMB in thousands)

% of Revenue⁽¹⁾

137%

59%

45%

1,066%




237%

72%

203%

69%

32%



■ Selling and distribution expenses net of SBC

■ SBC

■ R&D expenses net of SBC

■ SBC

■ Administrative expenses net of SBC

■ SBC

■ Listing expenses


Notes:

1. Excluding SBC and listing expenses

Accounts Receivable / Accounts Payable Turnover


Accounts Receivable Turnover

(Turnover Days)



Accounts Payable Turnover

(Turnover Days)



Notes:

1. The calculation result of the average trade receivables turnover days in 2021 is 0.58 days, and the average trade receivables is 288,000 yuan, which is not suitable for comparison
2. The average trade receivables turnover days for a period is equal to the arithmetic mean of the opening and closing trade receivables balances for the period divided by the revenue for the period multiplied by 360 days (for a full year period)
3. The average trade payables turnover days in a year is equal to the arithmetic mean of the trade payables balances at the beginning and end of the relevant year divided by the cost of sales and multiplied by 360 days (for a full year period)



SECTION 4

Summary



Summary

1

The Most Comprehensive Product Portfolio in China

- Provide full suite solutions for doctors and patients
- Diversified product portfolio to reduce product revenue concentration
- Attract high-quality dealers and enhance competitive advantage



2

Strong In-house R&D Capabilities

- Dedicated to innovative and efficient product development
- Attract R&D personnel and partners
- Independent IP laying a solid foundation for promoting overseas markets
- Provide the foundation to extend to other minimally invasive interventional fields



3

Leading R&D And Manufacturing Proprietary Technology Platform

- Promoting technological breakthroughs to ensure premium quality
- Effectively improve production efficiency and control costs
- Provide cost advantage of mass production for centralized procurement



4

Efficient Commercialization Capabilities With Increasingly Sophisticated Distribution Network and KOL

- Efficient market access for the ever-growing product pipeline
- Innovate products with the advantages of the collaboration of doctors and industry



Become China's Leading Minimally Invasive Medical Device Platform

Appendix

Please refer to the 2021 Annual Report for further information

[Click to download the 2021 Annual Report](#)



归创通桥
ZYLOX-TONBRIDGE

Consolidated Statements of Profit or Loss

Year ended December 31, 2021

<i>RMB'000</i>	Year ended December 31, 2021	
	2021	2020
Revenue	177,912	27,631
Cost of sales	(46,031)	(11,344)
Gross Profit	131,881	16,287
Selling and distribution expenses	(95,269)	(20,453)
Administrative expenses	(100,599)	(30,992)
Research and development expenses	(168,100)	(72,065)
Other income	15,286	9,997
Other expenses	(712)	(257)
Other gains/(losses) - net	5,058	(2,679)
Net impairment losses on financial assets	(21)	-
Operating loss	(212,476)	(100,162)
Finance income	13,094	360
Finance costs	(307)	(666)
Finance income/(costs) – net	12,787	(306)
Loss before income tax	(199,689)	(100,468)
Income tax expense	-	-
Loss for the year	(199,689)	(100,468)
Loss attributable to equity holders of the Company	(199,689)	(100,468)

Consolidated Balance Sheet

Year ended December 31, 2021

RMB'000	As at	
	December 31, 2021	December 31, 2020
Non-current assets		
Property, plant and equipment	178,270	105,224
Right-of-use assets	34,115	16,950
Intangible assets	4,889	7,556
Prepayments	6,804	4,099
Total non-current assets	224,078	133,829
Current assets		
Inventories	57,272	28,993
Prepayments, other receivables and other current assets	37,616	23,764
Trade receivables	46	129
Financial assets at fair value through profit or loss	10,515	157,700
Term deposit	1,500,000	100,000
Cash and cash equivalents	1,418,359	59,556
Total current assets	3,024,208	370,142
Total assets	3,248,286	503,971
Non-current liabilities		
Borrowings	–	26,250
Lease liabilities	6,509	1,396
Total non-current liabilities	6,509	27,646
Current liabilities		
Trade and other payables	86,307	43,658
Contract liabilities	3,420	134
Borrowings	–	3,750
Lease liabilities	2,896	2,825
Other current liabilities	4,480	1,264
Total current liabilities	97,103	51,631
Total liabilities	103,612	79,277
Equity attributable to equity holders of the Company		
Paid-in capital/share capital	332,401	225,062
Other reserves	2,270,033	561,147
Treasury share	9,149	–
Accumulated losses	(289,618)	(361,515)
Total equity	3,144,674	424,694
Total equity and liabilities	3,248,286	503,971

Product Portfolio for Neurovascular Interventional Devices in China Market

	Product	Stage				Expected Commercial Launch Year
		Design	Type Testing	Clinical	Registrational & Approval	
Intracranial Ischemic Stroke	Thrombite® Clot Retriever Device (Thrombite® CRD) ★	[Progress bar: 100%]				Launched
	Clot Retriever Device II	[Progress bar: 50%]		Exempted from clinical trial requirement		2023
	Balloon Guiding Catheter (BGC)	[Progress bar: 100%]		Exempted from clinical trial requirement		Launched
	Aspiration Catheter	[Progress bar: 80%]				2022
	Aspiration Pump System	[Progress bar: 50%]		Exempted from clinical trial requirement		2023
Intracranial Stenosis	Intracranial PTA balloon catheter (Rx)	[Progress bar: 100%]		Exempted from clinical trial requirement		Launched
	Intracranial PTA balloon catheter (OTW)	[Progress bar: 50%]		Exempted from clinical trial requirement		2023
	Microcatheter for Intracranial Stent	[Progress bar: 70%]		Exempted from clinical trial requirement		2023
	Intracranial Drug Coated Balloon Catheter	[Progress bar: 90%]				2024
	Intracranial Stent	[Progress bar: 80%]				2025
Intracranial Hemorrhagic Stroke	Neurovascular Embolization Coils	[Progress bar: 100%]				Launched
	Mechanical Detachable Coil II	[Progress bar: 50%]		Exempted from clinical trial requirement		2023
	Microcatheter for Coiling	[Progress bar: 100%]		Exempted from clinical trial requirement		Launched
	Microcatheter for Flow Diverter	[Progress bar: 50%]		Exempted from clinical trial requirement		2023
	Flow Diverter	[Progress bar: 80%]				2024
	Self-expandable Intracranial Stent	[Progress bar: 50%]				2025
Intracranial Access	SilverSnake® Intracranial Support Catheter	[Progress bar: 100%]		Exempted from clinical trial requirement		Launched
	Microcatheter for Clot Retriever	[Progress bar: 100%]		Exempted from clinical trial requirement		Launched
	Distal Access Catheter	[Progress bar: 100%]		Exempted from clinical trial requirement		Launched
	SilverSnake® Standard Intracranial Support Catheter	[Progress bar: 100%]		Exempted from clinical trial requirement		Launched
	Neurovascular Guidewire	[Progress bar: 50%]		Exempted from clinical trial requirement		2022
	Radial Access Catheter	[Progress bar: 30%]		Exempted from clinical trial requirement		2024
Carotid Artery Stenosis	Carotid RX PTA Balloon Catheter	[Progress bar: 100%]		Exempted from clinical trial requirement		Launched
	Embolic Protection System	[Progress bar: 50%]		Exempted from clinical trial requirement		2023
	Carotid Stent	[Progress bar: 50%]				2025

★ Core Product; further R&D includes post-approval study, product improvement and indication expansion

Product Portfolio for Peripheral Vascular Interventional Devices and Vascular Closure Devices in China Market

	Product	Stage				Expected Commercial Launch Year	
		Design	Type Testing	Clinical	Registrational & Approval		
Arterial	UltraFree® Drug Coated PTA Balloon Catheter (UltraFree® DCB) ★	Completed				Launched	
	Second Generation UltraFree® Drug Coated PTA Balloon Catheter	Completed		Exempted from clinical trial requirement	Completed	2022	
	PTA Balloon Catheter	Completed		Exempted from clinical trial requirement	Completed	Launched	
	Second Generation PTA Balloon Catheter	Completed		Exempted from clinical trial requirement		2022	
	Peripheral Stent System	Completed				2023	
	Peripheral Drug-Eluting Stent System	Completed				2025	
	Endovascular Snare	Completed		Exempted from clinical trial requirement	Completed	Launched	
	PTA Scoring Balloon Catheter	Completed				2024	
	Multi-spot Stent System	Completed				2024	
	Drug Coated PTA Balloon Catheter-BTK	Completed				2024	
	IVL System	Completed				2025	
	Venous	Snare Retrieval Kit for IVC Filter	Completed		Exempted from clinical trial requirement	Completed	Launched
		Endovenous Radiofrequency Ablation (RFA) Catheter	Completed				2022
Radiofrequency Generator		Completed				2023	
PTA Balloon Catheter Large Diameter		Completed		Exempted from clinical trial requirement	Completed	2022	
Infusion Catheter		Completed		Exempted from clinical trial requirement		2023	
Peripheral Venous Stent System		Completed				2023	
Varicose Vein Closure System		Completed				2024	
Peripheral Thrombectomy System		Completed				2024	
Retrievable Inferior Vena Cava Filter		Completed				2022	
Mechanical Thrombectomy Device		Completed				2025	
Hemodialysis Access	High Pressure PTA Balloon Catheter	Completed		Exempted from clinical trial requirement	Completed	Launched	
	Second Generation High Pressure PTA Balloon Catheter	Completed		Exempted from clinical trial requirement		2022	
	Drug Coated PTA Balloon Catheter-AV Fistula	Completed				2024	
Aortic Intervention	Thoracic Aorta Stent Graft System	Completed				2025	
Peripheral Embolization Intervention	Peripheral Detachable Embolization Coils	Completed				2024	
Radiological Intervention	TIPS Access Set	Completed		Exempted from clinical trial requirement		2023	
	TIPS Endoprosthesis	Completed				2024	
Vascular Closure Devices	Suture-mediated Closure System	Completed				2023	
	Vascular Closure System	Completed				2024	

★ Core Product; further R&D includes post-approval study, product improvement and indication expansion